Online inquiry

IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ3185MR)

This product GTTS-WQ3185MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ANPEP gene. The antibody can be applied in Mesothelioma, Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001150.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 290
UniProt ID P15144
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ3185MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4279MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ7990MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ11140MR IVTScrip™ mRNA-Anti-IFNA1, MDX-1103(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA MDX-1103
GTTS-WQ10106MR IVTScrip™ mRNA-Anti-MET, LA480(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA LA480
GTTS-WQ3974MR IVTScrip™ mRNA-Anti-LTB&TNFSF14, BG9924(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BG9924
GTTS-WQ9127MR IVTScrip™ mRNA-Anti-MUC1, IMGN242(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA IMGN242
GTTS-WQ10306MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA LGT209
GTTS-WQ12365MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA N63Ab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW